Based on the key indicators related to Tarsus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Tarsus Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Tarsus Pharmaceuticals' Property Plant And Equipment Gross is comparatively stable compared to the past year. Short and Long Term Debt Total is likely to gain to about 33.3 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 131.1 M in 2024. Key indicators impacting Tarsus Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Tarsus Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Tarsus Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tarsus Pharmaceuticals.
Net Income
(129.1 Million)
Tarsus
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Change To Inventory
Other Non Cash Items
Sale Purchase Of Stock
Change Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Non Currrent Assets Other
Other Assets
Inventory
Short Term Debt
Other Liab
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Non Current Liabilities Other
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Cost Of Revenue
Interest Income
Probability Of Bankruptcy
Understanding current and past Tarsus Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tarsus Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Tarsus Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Tarsus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tarsus Pharmaceuticals. Check Tarsus Pharmaceuticals' Beneish M Score to see the likelihood of Tarsus Pharmaceuticals' management manipulating its earnings.
Tarsus Pharmaceuticals Stock Summary
Tarsus Pharmaceuticals competes with Aldeyra, Travere Therapeutics, Eton Pharmaceuticals, Connect Biopharma, and Acumen Pharmaceuticals. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Tarsus Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Tarsus Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Tarsus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Tarsus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tarsus Pharmaceuticals competition to find correlations between indicators driving Tarsus Pharmaceuticals's intrinsic value. More Info.
Tarsus Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Tarsus Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tarsus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Tarsus Pharmaceuticals Systematic Risk
Tarsus Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tarsus Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Tarsus Pharmaceuticals correlated with the market. If Beta is less than 0 Tarsus Pharmaceuticals generally moves in the opposite direction as compared to the market. If Tarsus Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tarsus Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tarsus Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Tarsus Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Tarsus Pharmaceuticals Thematic Clasifications
Tarsus Pharmaceuticals is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Today, most investors in Tarsus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tarsus Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tarsus Pharmaceuticals growth as a starting point in their analysis.
Tarsus Pharmaceuticals November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tarsus Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tarsus Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tarsus Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Tarsus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tarsus Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.